<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Allos Therapeutics</title>
	<atom:link href="http://www.stockbloghub.com/tag/allos-therapeutics/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HNAB) Hana Bioscience Encouraging Phase II Results</title>
		<link>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616</link>
		<comments>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616#comments</comments>
		<pubDate>Tue, 09 Nov 2010 18:28:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Hana Biosciences Inc]]></category>
		<category><![CDATA[HNAB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58616</guid>
		<description><![CDATA[Written by Grant Zeng, CFA Hana Biosciences Inc. ( HNAB ) A decent pipeline with late stage candidates&#8230; South San Francisco, CA based Hana Biosciences, Inc. (Hana) is a late development stage biopharmaceutical company which is focused on two cancer care areas: cancer therapeutics and cancer supportive care. The company’s lead cancer therapeutic candidate is Marqibo (vincristine sulfate liposome injection), a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine, for the treatment of relapsed/refractory adult acute lymphoblastic leukemia (ALL). Hana presented results from the registration-enabling Phase II clinical trial (rALLY) of Marqibo for ALL in June 2010 at the ASCO meeting. The data were compelling. Marqibo was administered as third-, fourth-, fifth-, and sixth-line single-agent therapy for ALL patients. The trial achieved 35% overall response rate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics Drug Earns FDA Orphan Status</title>
		<link>http://www.stockbloghub.com/2010/05/24/alth-allos-therapeutics-drug-earns-fda-orphan-status/37703</link>
		<comments>http://www.stockbloghub.com/2010/05/24/alth-allos-therapeutics-drug-earns-fda-orphan-status/37703#comments</comments>
		<pubDate>Tue, 25 May 2010 03:34:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37703</guid>
		<description><![CDATA[Recently, Allos Therapeutics (ALTH) received orphan drug status from the US Food and Drug Administration (FDA) for pralatrexate to treat bladder cancer. The drug is being studied in a phase II clinical trial in patients with advanced or metastatic transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer. The orphan drug designation brings with it seven years of marketing exclusivity in the US during which the FDA may not approve another company’s application for any drug containing the same active ingredient and for the same orphan indication. Additionally, this status also provides several other benefits such as advice on clinical trials, tax credits for research expenses and grant funding for research of rare diseases. Huge potential lies in the area of bladder cancer due to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/alth-allos-therapeutics-drug-earns-fda-orphan-status/37703/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics&#8217; Earnings Loss Narrows</title>
		<link>http://www.stockbloghub.com/2010/05/09/alth-allos-therapeutics-earnings-loss-narrows/36646</link>
		<comments>http://www.stockbloghub.com/2010/05/09/alth-allos-therapeutics-earnings-loss-narrows/36646#comments</comments>
		<pubDate>Mon, 10 May 2010 05:31:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36646</guid>
		<description><![CDATA[Allos Therapeutics’ (ALTH) first quarter fiscal 2010 loss per share came in at 20 cents, compared to the Zacks Consensus Estimate of a loss of 22 cents and a loss of 19 cents reported in the year-ago period. The company recorded $7.4 million in sales during the quarter. In January 2010, Allos launched Folotyn in the US. The drug received accelerated approval from the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Allos has agreed to conduct additional clinical trials to further verify the benefit of Folotyn. The requirement of additional trials comes with accelerated FDA approval as the agency requires further studies after the launch to confirm the drug&#8217;s benefits. Operating expenses during the quarter increased 77.5% to $27.2 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/09/alth-allos-therapeutics-earnings-loss-narrows/36646/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics&#8217; Earnings Report Extends Losses</title>
		<link>http://www.stockbloghub.com/2010/03/03/alth-allos-therapeutics-earnings-report-extends-losses/29459</link>
		<comments>http://www.stockbloghub.com/2010/03/03/alth-allos-therapeutics-earnings-report-extends-losses/29459#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:49:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29459</guid>
		<description><![CDATA[Allos Therapeutics’ (ALTH) fourth quarter loss per share came in at 22 cents, worse than the Zacks Consensus Estimate of 20 cents and a loss of 18 cents reported in the year-ago period. For 2009, the company reported a loss per share of 81 cents compared to 69 cents in 2008. In Sep 2009, Allos received accelerated approval from the US Food and Drug Administration (FDA) for Folotyn for the treatment of patients with relapsed or refractory PTCL. During the third quarter conference call, the company stated the pricing of the drug &#8211; the average wholesale acquisition cost as $3,125 for the 20 mg vial and $6,250 for the 40 mg vial. Allos has agreed to conduct additional clinical trials to further verify the benefit of Folotyn. The requirement of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/alth-allos-therapeutics-earnings-report-extends-losses/29459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation Expands into Cancer Drugs</title>
		<link>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207</link>
		<comments>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:29:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25207</guid>
		<description><![CDATA[Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal is aimed at bolstering Celgene’s portfolio of cancer drugs. The deal is expected to be neutral to Celgene’s earnings in 2010 and accretive in 2011. Gloucester, founded in 2003, focused on developing new therapies to fulfill unmet medical needs in cancer treatment. The acquisition adds Istodax (romidepsin) to Celgene’s already established cancer portfolio. Istodax received clearance from the U.S. Food and Drug Administration (FDA) in November 2009 for treating CTCL patients who have received at least one prior systemic therapy. Celgene is expected to launch the drug in the first half of this year. Furthermore, it will pursue the European approval for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/celg-celgene-corporation-expands-into-cancer-drugs/25207/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Positive Data from Allos Therapeutics&#8217; Folotyn</title>
		<link>http://www.stockbloghub.com/2009/12/08/alth-positive-data-from-allos-therapeutics-folotyn/22196</link>
		<comments>http://www.stockbloghub.com/2009/12/08/alth-positive-data-from-allos-therapeutics-folotyn/22196#comments</comments>
		<pubDate>Tue, 08 Dec 2009 19:04:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22196</guid>
		<description><![CDATA[Allos Therapeutics (ALTH) recently released data on Folotyn (pralatrexate injection) from the PROPEL trial, which was conducted with patients suffering from relapsed or refractory peripheral T-cell lymphoma (PTCL). In addition, the company announced preliminary results from its phase 1/2 study of Folotyn in combination with gemcitabine for the treatment of patients with relapsed or refractory lymphoproliferative malignancies. The data were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. Earlier, in September 2009, Folotyn received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory PTCL. Following the approval, Folotyn became Allos’ first drug to receive FDA approval. This was a major breakthrough for the company as prior to Folotyn, there was no approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/alth-positive-data-from-allos-therapeutics-folotyn/22196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation to Expand</title>
		<link>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235</link>
		<comments>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235#comments</comments>
		<pubDate>Tue, 08 Dec 2009 18:50:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22235</guid>
		<description><![CDATA[Celgene Corporation (CELG) recently announced that it will purchase the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal is aimed at bolstering Celgene’s portfolio of cancer drugs. The transaction, which has been approved by the Board of Directors of both companies, is expected to be completed in the first quarter of 2010. The deal is expected to be neutral to Celgene’s earnings in 2010 and accretive in 2011. Gloucester, founded in 2003, focuses on developing new therapies aimed at fulfilling unmet medical needs for cancer treatment. The private entity focuses on developing therapies for cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and other hematological malignancies. The company’s lead drug Istodax (romidepsin) got U.S. Food and Drug Administration (FDA) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/celg-celgene-corporation-to-expand/22235/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics Reports Earnings in Line</title>
		<link>http://www.stockbloghub.com/2009/11/04/alth-allos-therapeutics-reports-earnings-in-line/19658</link>
		<comments>http://www.stockbloghub.com/2009/11/04/alth-allos-therapeutics-reports-earnings-in-line/19658#comments</comments>
		<pubDate>Thu, 05 Nov 2009 00:00:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19658</guid>
		<description><![CDATA[Allos Therapeutics’ (ALTH) third quarter loss per share came in at 21 cents, in line with the Zacks Consensus Estimate. However, the loss increased compared to the net loss of 16 cents reported in the year ago period. Loss increased primarily due to a 41% rise in operating expense. The huge increase in general and administrative expenses by 113% led to a rise in operating expenses. The quarter has been quite significant for Allos. In September, the company received accelerated approval from the US Food and Drug Administration (FDA) for pralatrexate (Folotyn) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Folotyn is Allos&#8217; first drug to receive FDA approval. While the drug is available to patients since October, the commercial launch is scheduled for January ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/alth-allos-therapeutics-reports-earnings-in-line/19658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics Closes New Share Offering</title>
		<link>http://www.stockbloghub.com/2009/10/16/alth-allos-therapeutics-closes-new-share-offering/17777</link>
		<comments>http://www.stockbloghub.com/2009/10/16/alth-allos-therapeutics-closes-new-share-offering/17777#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17777</guid>
		<description><![CDATA[Yesterday, Allos Therapeutics (ALTH) announced the closure of an underwritten public offering of 14 million shares of newly issued common stock at $7.1 per share. The company received net proceeds of $93 million after deducting issue related expenses. We had forecasted that Allos would need to raise funds based on its cash position and requirements. The proceeds of the issue will be primarily used to support the commercialization of Folotyn (pralatrexate injection), other research and developmental activities and general corporate purposes. Earlier, in September, Allos received accelerated approval from the US Food and Drug Administration (FDA) for Folotyn for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Folotyn is Allos&#8217; first drug to receive FDA approval. While the drug will be available to patients in October, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/alth-allos-therapeutics-closes-new-share-offering/17777/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos Therapeutics Earns Accelerated Drug Approval</title>
		<link>http://www.stockbloghub.com/2009/10/06/alth-allos-therapeutics-earns-accelerated-drug-approval/16328</link>
		<comments>http://www.stockbloghub.com/2009/10/06/alth-allos-therapeutics-earns-accelerated-drug-approval/16328#comments</comments>
		<pubDate>Tue, 06 Oct 2009 18:00:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com.php5-2.dfw1-2.websitetestlink.com/?p=16328</guid>
		<description><![CDATA[In a major breakthrough, Allos Therapeutics (ALTH) received FDA-accelerated approval for Folotyn (pralatrexate injection) last week. The company was seeking approval of the drug for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Folotyn becomes Allos&#8217; first drug to receive FDA approval. While the drug will be available to patients within a month, the commercial launch is scheduled for January 2010. Allos is increasing its sales force from the current level of 25 to 50, and doing the necessary preparations for its launch. Allos has agreed to conduct additional clinical trials to further verify the benefit of Folotyn. The requirement of additional trials comes with accelerated FDA approval as the agency requires further studies after the launch to confirm the drug&#8217;s benefits to patients. Earlier this ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/06/alth-allos-therapeutics-earns-accelerated-drug-approval/16328/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Allos TherapeuticsAwaits FDA Report on Folotyn</title>
		<link>http://www.stockbloghub.com/2009/09/24/alth-allos-therapeuticsawaits-fda-report-on-folotyn/15984</link>
		<comments>http://www.stockbloghub.com/2009/09/24/alth-allos-therapeuticsawaits-fda-report-on-folotyn/15984#comments</comments>
		<pubDate>Thu, 24 Sep 2009 20:49:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15984</guid>
		<description><![CDATA[We are awaiting the US Food and Drug Administration’s (FDA) decision regarding Allos Therapeutics’ (ALTH) lymphoma drug Folotyn. The company, which is seeking approval of Folotyn for the treatment of relapsed or refractory peripheral T-Cell lymphoma (PTCL), was assigned a Prescription Drug User Fee Act (PDUFA) date of Sept. 24. We are optimistic about the approval of Folotyn based on the FDA advisory panel’s favorable recommendation earlier this month. The board voted 10-4 in favor of the drug and said that new treatments were required for the disease. However, we are still wary as the studies conducted by Allos did not record robust data. The number of patients who responded to the treatment was rather low (27% of 115 patients) with the majority of them responding only partially. Moreover, effect ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/alth-allos-therapeuticsawaits-fda-report-on-folotyn/15984/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) FDA Panel Gives Favorable Recommendation for Allos Therapeutics&#8217; Drug</title>
		<link>http://www.stockbloghub.com/2009/09/03/alth-fda-panel-gives-favorable-recommendation-for-allos-therapeutics-drug/14393</link>
		<comments>http://www.stockbloghub.com/2009/09/03/alth-fda-panel-gives-favorable-recommendation-for-allos-therapeutics-drug/14393#comments</comments>
		<pubDate>Thu, 03 Sep 2009 23:56:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14393</guid>
		<description><![CDATA[Yesterday, the US Food and Drug Administration’s (FDA) panel came out with a favorable recommendation regarding the approval of Allos Therapeutics’ (ALTH) lymphoma drug Folotyn (pralatrexate). The company is seeking approval of Folotyn for the treatment of relapsed or refractory peripheral T-Cell lymphoma (PTCL). Although the FDA is not required to follow the panel’s advice, it generally does so. The agency is supposed to take a final decision on the drug by Sept 24. The FDA panel voted 10-4 in favor of the drug along with stating that new treatments are required for the disease. Studies conducted by the company did not record robust data. The number of patients who responded to the treatment was quite less (27% of 115 patients) with majority of them responding only partially. Benefit of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/alth-fda-panel-gives-favorable-recommendation-for-allos-therapeutics-drug/14393/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALTH) Crucial Time for Allos Therapeutics</title>
		<link>http://www.stockbloghub.com/2009/08/24/alth-crucial-time-for-allos-therapeutics/13206</link>
		<comments>http://www.stockbloghub.com/2009/08/24/alth-crucial-time-for-allos-therapeutics/13206#comments</comments>
		<pubDate>Mon, 24 Aug 2009 21:17:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13206</guid>
		<description><![CDATA[We are awaiting the decision of the US Food and Drug Administration&#8217;s (FDA) cancer advisory committee regarding approval of Allos Therapeutics’ (ALTH) Pralatrexate at a meeting scheduled for September 2, 2009. The company is seeking FDA approval for Pralatrexate for the treatment of patients with T-cell lymphoma. Although the FDA is not bound to follow the decision of the advisory panel, it generally does so. A positive recommendation from the panel increases the possibility of gaining approval for pralatrexate from the FDA. The final decision is expected by September 24th. In February this year, Allos Therapeutics came out with encouraging data from the clinical trials of pralatrexate and filed a New Drug Application (NDA) in March based on it. Pralatrexate has &#8220;orphan drug&#8221; status from the FDA and European Medicines ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/alth-crucial-time-for-allos-therapeutics/13206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

